Department of Cardiovascular Surgery, Ege University Hospital, Izmir, Turkey.
Artif Organs. 2013 Sep;37(9):763-7. doi: 10.1111/aor.12164. Epub 2013 Sep 11.
Pulmonary hypertension (PH) is considered as a risk factor for morbidity and mortality in patients undergoing heart transplantation. Recently, left ventricular assist device (LVAD) implantation has been increasingly used in reducing pulmonary artery pressure (PAP) in patients with PH unresponsive to medical therapy. Herein, we aimed to compare the efficacy of continuous-flow and pulsatile-flow blood pumps on the improvement of PH in mechanical circulatory support patients. Twenty-seven patients with end-stage heart failure who underwent LVAD implantation surgery were enrolled. Fifteen of them (55.6%) had continuous-flow pump (HeartWare Ventricular Assist System, HeartWare, Inc., Miramar, FL, USA), and 12 of them (44.4%) had pulsatile pump (Berlin Heart EXCOR ventricular assist device, Berlin Heart AG, Berlin, Germany). The efficacy of LVADs on the improvement of PH was compared between continuous-flow and pulsatile pumps by the evaluation of systolic PAP, tricuspid annular plane systolic excursion (TAPSE), right ventricular systolic motion (RVSM), right ventricular ejection fraction (RVEF), and grade of tricuspid insufficiency (TI) for each of the study participants. All of the 15 patients who underwent continuous-flow blood pump implantation surgery (Group 1) were male with a mean age of 46.9 ± 11.7 years, and in pulsatile-flow blood pump implanted participants (Group 2), the mean age was 40.6 ± 16.8 years, all of whom were also male (P=0.259). Mean follow-up was 313.7 ± 241.3 days in Group 1 and 448.7 ± 120.7 days in Group 2 (P=0.139). In Group 1, mean preoperative and postoperative systolic PAP were measured as 51.7 ± 12.2 mm Hg and 22.2 ± 3.4 mm Hg, respectively, while those in Group 2 were 54.5 ± 7.5 mm Hg and 33.9 ± 6.4 mm Hg, respectively. A significantly greater decrease in systolic PAP was noticed in patients with continuous-flow blood pumps (P=0.023); however, no statistically significant difference was found when we considered the change in TAPSE between study groups (P=0.112). A statistical significance in the alteration of RVEF, RVSM, and the grade of TI during study visits was not found between the study groups (P=0.472, P=0.887, and P=0.237, respectively). Although the two studied types of LVADs were found to be effective in reducing PAP in heart transplantation candidates with PH, lesser postoperative systolic PAP values were achieved in patients who underwent continuous-flow pump implantation surgery.
肺动脉高压(PH)被认为是心脏移植患者发病率和死亡率的一个风险因素。最近,左心室辅助装置(LVAD)的植入已越来越多地用于降低对药物治疗无反应的 PH 患者的肺动脉压(PAP)。在此,我们旨在比较离心泵和搏动流血泵在改善机械循环支持患者 PH 方面的效果。
我们纳入了 27 例接受 LVAD 植入手术的终末期心力衰竭患者。其中 15 例(55.6%)使用离心泵(HeartWare 心室辅助系统,HeartWare,Inc.,Miramar,FL,美国),12 例(44.4%)使用搏动泵(柏林心脏 EXCOR 心室辅助装置,柏林心脏 AG,柏林,德国)。通过评估收缩期肺动脉压、三尖瓣环平面收缩期位移(TAPSE)、右心室收缩运动(RVSM)、右心室射血分数(RVEF)和三尖瓣关闭不全(TI)程度,比较两种 LVAD 在改善 PH 方面的效果。
所有接受离心泵植入手术的 15 例患者(组 1)均为男性,平均年龄为 46.9±11.7 岁,接受搏动流血泵植入的患者(组 2)平均年龄为 40.6±16.8 岁,均为男性(P=0.259)。组 1 的平均随访时间为 313.7±241.3 天,组 2 为 448.7±120.7 天(P=0.139)。组 1 术前和术后的平均收缩期肺动脉压分别为 51.7±12.2mmHg 和 22.2±3.4mmHg,组 2 分别为 54.5±7.5mmHg 和 33.9±6.4mmHg。组 1 患者的收缩期肺动脉压下降更为显著(P=0.023),但两组间 TAPSE 的变化无统计学意义(P=0.112)。两组患者在研究期间的 RVEF、RVSM 和 TI 分级的改变均无统计学意义(P=0.472,P=0.887,P=0.237)。
尽管两种研究类型的 LVAD 都被发现能有效降低 PH 心脏移植候选者的 PAP,但接受离心泵植入手术的患者术后收缩期肺动脉压值较低。